BioSpace

JPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer

Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development ...
AZ Central

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the ...
Joplin Globe

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist ...
Pocono Record

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity

NEWARK, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, ...